CKD Bio Q3 Revenue Falls 14% Year on Year

PUBT · 1d ago
CKD Bio Q3 Revenue Falls 14% Year on Year
  • CKD Bio’s third-quarter 2026 operating loss widened 308.6% year over year to 5.99 billion won.
  • Revenue fell 14% year over year to 29.33 billion won.
  • Net loss widened 381% year over year to 10.48 billion won.
  • First-nine-month operating results swung to a 12.7 billion won loss from a 3.5 billion won profit a year earlier.
  • Revenue for that period declined 5.7% year over year to 111.11 billion won.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CKD Bio Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800591), on October 30, 2026, and is solely responsible for the information contained therein.